NEW YORK ( TheStreet) -- CHANGE IN RATINGSAutomatic Data Processing ( ADP) downgraded at UBS to Neutral from Buy, UBS said. $59 price target. Full valuation, limited near term catalysts. Albany Molecular Research ( AMRI) upgraded to hold at TheStreet Ratings. Approach Resources ( AREX) upgraded at JP Morgan from Neutral to Overweight, JP Morgan said. Company can grow faster than its peers and trades at a relative discount. Anixter ( AXE) downgraded at Credit Suisse from Neutral to Underperform, Credit Suisse said. $60 price target. Company is seeing lower datacom spending and industrial growth in Europe. BNY Mellon ( BK) rated new Buy at Citigroup. $27 price target. Valuation and expect FX litigation to dissipate some of risk premium. Cognex ( CGNX) downgraded at Piper from Neutral to Underweight, Piper Jaffray said. $27 price target. Growth could be hurt my macro headwinds. DirecTV ( DTV) upgraded at Hudson Square from Hold to Buy, Hudson Square said. $60 price target. Fusion-IO ( FIO) rated new Buy at Wunderlich. $38 price target. Company can continue to grow on its own or may eventually be acquired. Genomic Health ( GHDX) rated new Outperform at Credit Suisse. $43 price target. Company can continue to gain market share. Impax Laboratories ( IPXL) downgraded at ThinkEquity from Buy to Hold, ThinkEquity said. Valuation call, based on a $25 price target. Marriot International ( MAR) downgraded at KBW to Market Perform from Outperform, KBW said. $42 price target. Valuation and heightened economic concerns. Martin Marietta ( MLM) downgraded at Keybanc from Buy to Hold, Keybanc said. Valuation call. Myriad Genetics ( MYGN) rated new Neutral at Credit Suisse. $28 price target. Near and long term concerns overshadow underlying organic growth. Nokia ( NOK) downgraded at BMO from Market Perform to Underperform, BMO Capital said. $2 price target. Do not expect new phones to gain much traction. Northern Trust ( NTRS) rated new Neutral at Citigroup. $50 price target. Struggle to see upside from current price. Paychex ( PAYX) downgraded at Citigroup to Sell from Neutral, Citigroup said. $30.50 price target. Modest growth can't support rich valuation. Paychex downgraded at UBS to Neutral from Buy, UBS said. $35 price target. Full valuation, challenging backdrop.